Pluristem (PSTI) Receives Approval to Commence PLX-PAD Phase II in Germany
- Wall St. rallies, led by banks and energy stocks
- Unusual 11 Mid-Day Movers 2/12: (ICPT) (NEWS) (MERC) Higher; (LPLA) (SCSS) (SUNE) Lower
- Intercept Pharma (ICPT) Said to Explore Sale Following Interest
- Deutsche Bank (DB) Plans EUR 3B, $2B Debt Buyback
- AIG (AIG) Misses Q4 EPS by 19c; Raises Buyback to $5B, Announces Dividend Increase
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) announced that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication (IC). IC is a subset of Peripheral Artery Disease (PAD). According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Committee to Discuss Clovis Oncology's (CLVS) Rociletinib NDA on April 12th
- Immersion (IMMR) Files Complaints vs Apple and AT&T with ITC
- Delta Air Lines (DAL) Announces Record Profit Sharing for Employees
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!